SML1284
Efavirenz Ready Made Solution
10 mg/mL in DMSO
别名:
(4S)-6-Chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one, (4S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
SMILES string
FC(F)(F)[C@]2(OC(=O)Nc3c2cc(cc3)Cl)C#CC1CC1
InChI
1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
InChI key
XPOQHMRABVBWPR-ZDUSSCGKSA-N
form
DMSO solution
concentration
10 mg/mL in DMSO
shipped in
dry ice
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Efavirenz is a nonnucleoside reverse transcriptase inhibitor (NNRTI).
Efavirenz is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Efavirenz is an anti-HIV drug, commonly used in combination therapy for AIDs treatment. Efavirenz is part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
The plasma levels of this drug can determine the failure of treatment and CNS (central nervous system) side-effects in patients infected with HIV (human immunodeficiency virus).
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 2 - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
188.6 °F
flash_point_c
87 °C
法规信息
新产品
此项目有
C Marzolini et al.
AIDS (London, England), 15(1), 71-75 (2001-02-24)
Limited information exists on the clinical usefulness of drug level monitoring for efavirenz, a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI). The aim of this study was to determine whether efavirenz plasma concentration monitoring could predict treatment failure and central nervous
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持